Effect of insulin glargine and lixisenatide and insulin degludec and liraglutide on glucose variability and oxidative stress in type 2 diabetes patients

Effect of insulin glargine and lixisenatide and insulin degludec and liraglutide on glucose variability and oxidative stress in type 2 diabetes patients - Effect of insulin glargine and lixisenatide and insulin degludec and liraglutide on glucose variability and oxidative stress in type 2 diabetes patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043068

Enrollment

Registered

2021-01-20

Start date

2021-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

insulin degludec and liraglutide insulin glargine and lixisenatide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)a diagnosis of type 2 diabetes mellitus 2)20 years and over 3)HbA1c 7.0% or more 4)treatment with iusulin glargine and lixisenatide for 12weeks or longer

Exclusion criteria

Exclusion criteria: 1)the use of steroids or anti-inflammatory drugs, 2)diabetic ketosis and coma within 3 months before the study, 3)severe infection, severe trauma, pre-and post-operation, 4)an estimated glomerular filtration rate are within 30mL/min/1.73m2, 5)malignancy, 6)pregnancy 7)Patients who are judged as inappropriate for inclusion by phsicians

Design outcomes

Primary

Measure	Time frame
oxidative stress and glucose variability	—

Countries

Japan

Contacts

Public ContactMakoto Ohara

Showa University School of Medicine Division of Diabetes and Endocrinology, Department of Internal Medicine

s6018@nms.ac.jp03-3784-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026